Revive Therapeutics Ltd.
RVVTF
$0.02
$0.007.53%
OTC PK
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 64.12% | 27.16% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 64.17% | 27.16% | |||
| Operating Income | -64.17% | -27.16% | |||
| Income Before Tax | -112.73% | 16.32% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -112.73% | 16.32% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -112.73% | 16.32% | |||
| EBIT | -64.17% | -27.16% | |||
| EBITDA | -64.12% | -27.16% | |||
| EPS Basic | -100.00% | 20.00% | |||
| Normalized Basic EPS | -150.00% | 33.33% | |||
| EPS Diluted | -100.00% | 20.00% | |||
| Normalized Diluted EPS | -150.00% | 33.33% | |||
| Average Basic Shares Outstanding | 0.00% | 1.48% | |||
| Average Diluted Shares Outstanding | 0.00% | 1.48% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||